Publications by authors named "Sze Yinn Lim"
Introduction: In the absence of an effective treatment for non-alcoholic steatohepatitis (NASH), a randomized, placebo-controlled trial (RCT) remains the current gold standard study design in NASH. As NASH is a largely asymptomatic disease, the side effects of potential therapies require careful evaluation, therefore a pooled rate of the adverse events (AEs) in placebo-treated patients serves as a useful comparator for safety. Therefore, we performed a systematic review and meta-analysis to estimate the rate of AEs among participants in the placebo arm of NASH RCTs.
View Article and Find Full Text PDFArticle Synopsis
- Chronic kidney disease (CKD) is a common complication following liver transplantation, impacting patient survival rates over time.
- A meta-analysis of 21 studies indicated that cumulative incidence of CKD increases significantly at 1, 3, and 5 years post-transplant, with stage 3-5 CKD affecting approximately 43.52% of patients by year 5.
- Key risk factors for developing CKD include age, female sex, diabetes, and previous acute kidney injury, highlighting the need for targeted renal-sparing immunosuppression in high-risk patients to improve clinical outcomes.